Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Caen

About this trial

MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of intracellular signalling pathways that govern cellular behaviour (Komatsu et al., 2023). They are widely implicated in oncogenesis, and in particular in mechanisms promoting cell migration, invasion and proliferation (Romano et al., 2021). Several preliminary studies have shown that serum levels of pro-oncogenic microRNAs correlate with tumor rates in gliomas (Jones et al., 2021; Levallet et al., 2022; Morokoff et al., 2020). Morokoff's study showed encouraging but insufficient results on the possibility of using microRNAs to differentiate radionecrosis versus recurrence. These results need to be consolidated prospectively, with homogeneous samples taken from all patients.

The aim of this study is to describe the evolution over time of plasma levels of pro-oncogenic microRNAs, after surgery for grade 4 glioma, in order to assess whether they can be used to identify false-positive recurrences on MRI (radionecrosis).

Eligibility criteria

Qualifiers

Major patient

Grade 4 diffuse glioma

Surgery in the neurosurgery department of Caen University Hospital

Patient affiliated to a social security scheme

Disqualifiers

- Patients who underwent biopsy (lack of material for study, limited interest of monitoring for these patients without surgical excision).

Patients with grade 1 circumscribed glioma or grade 2 or 3 diffuse glioma.

Other non-glial histologies, glioneuronal histology

Minor patients

Trial design

Treatments tested in this trial

  • Blood sample

Treatment groups

No treatment groups listed

Sponsors and collaborators